Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization

ZHANG Jian; WU Min; ZHANG Zi-sen; WANG Li-juan; ZHANG Hong-qiao; SHI Guang-yong; BA Nan; YAN Lin; ZHENG Xiao-ke; XING Xin

doi:10.13422/j.cnki.syfjx.2014130189

您当前的位置：

首页 >

文章列表页 >

Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization

更新时间：2024-01-04

- Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 13, Pages: 189-192(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014130189
  CLC： R735.7
- Published：2014
- 稿件说明：
移动端阅览
ZHANG Jian, WU Min, ZHANG Zi-sen, et al. Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 189-192.
DOI：

ZHANG Jian, WU Min, ZHANG Zi-sen, et al. Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 189-192. DOI： 10.13422/j.cnki.syfjx.2014130189.

摘要

目的：探讨养正消积胶囊对原发性肝癌肝动脉化疗栓塞（TACE）术后患者无进展生存期（PFS）的影响及作用机制。方法：将97例患者随机按住院顺序分为对照组47例和观察组50例。对照组服用复方斑蝥胶囊，3粒/次，2次/d。观察组服用养正消积胶囊，4粒/次，2次/d。疗程：直到疾病出现进展。记录无进展生存期；治疗前及治疗后3个月进行KPS评分及外周血T淋巴细胞亚群和自然杀伤细胞（NK）水平检测；检测治疗前及治疗后3个月血管内皮生长因子（VEGF）、成纤维细胞生长因子（FGF）和血甲胎蛋白（AFP）水平。结果：对照组PFS时间为（17.5±6.2）周，观察组为（21.3±6.9）周，观察组PFS长于对照组（P<0.01）；治疗后3个月对照组T淋巴细胞亚群（CD3+，CD4+，CD8+，CD4+/CD8+）和NK与治疗前比较变化不明显；观察组CD3+，CD4+，CD4+/CD8+，NK均比治疗前上升（P<0.01），治疗后3个月观察组CD3+，CD4+，CD4+/CD8+，NK高于对照组（P<0.01），CD8+低于对照组（P<0.01）；治疗后3个月两组血清VEGF，bFGF和AFP水平较治疗前下降（P<0.01），观察组血清VEGF，bFGF和AFP水平低于对照组（P<0.01）。结论：养正消积胶囊能延长原发性肝癌TACE术后患者无进展生存期，稳定了患者的生活质量，其作用机制可能与提高患者细胞免疫功能，抑制血管形成有关。

Abstract

Objective: Discuss the influence and mechanism of action of Yangzheng Xiaoji capsule to patients' progression free survival(PFS) in treating primary liver cancer after arterial chemoembolization. Method: Ninety-seven patients were randomly divided into control group (47 cases) and observation group (50 cases)by random number table.Patients in the control group received Fufang Banmao capsules

3 grains/time

2 times/day.Patients in the observation group received Yangzheng Xiaoji capsule

4 grains/time

2 times/day.Treatment was ending when progression of ill appeared.Progression free survival was recorded.Before treatment and at the third mouth after treatment

KPS was graded and level of T lymphocyte subpopulation of peripheral blood and natural killer cell(NK) were detected.vascular endothelial growth factor(VEGF)

fibroblast growth factor(FGF) and alpha fetal protein (AFP) were also detected. Result: PFS in control group were(17.5±6.2) weeks which were(21.3±6.9)weeks in observation group

which meat PFS in observation group was longer than in control group(P<0.01). Treatment 3 months after the control group T lymphocyte subsets (CD3+

CD4+

CD8+

CD4+/CD8+) and NK in control group changed indistinctively.But CD3+

CD4+

CD4+/CD8+and NK in observation group increased(P<0.01)

and which in observation group were higher than those in control group(P<0.01)

CD8+in observation group was lower than in control group(P<0.01).After 3 mouths of treatment

compared with the time before treatment

level of serous VEGF

bFGF and AFP decreased(P<0.01)

which in observation group were lower than those in control group(P<0.01). Conclusion: Yangzheng Xiaoji capsule can prolong patients' progression free survival in treating primary liver cancer after arterial chemoembolization

it stabilized patients' quality of lives

and its improving patients' cellular immune function and restraining angiogenesis.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Intervention of Fuzheng Huadu Xiaoai Decoction on 36 Cases Middle-late Stage Patients of Primary Liver Cancer

Mechanism of Kidney-tonifying and Liver-regulating Cyclical Therapy and Formula in Improving Endometrial Receptivity during "Implantation Window" in Rats with Polycystic Ovary Syndrome via miR-140-5p/VEGF Pathway

Protective Effect of Taohong Siwutang on Cerebral Ischemia-reperfusion Injury Based on A1/A2 Phenotype Transformation of Astrocytes Mediated by JAK2/STAT3 Pathway

Effect of Xiao Xianxiongtang on 5-FU-mediated Myocardial Fibrosis and Protein Expression of HIF-1α/VEGF Signaling Pathway in Mice

Mechanism of Shenqi Yiliu Prescription Combined with Cisplatin on H22 Liver Cancer-bearing Mice Based on NLRP3/Caspase-1/GSDMD Pyroptosis Pathway

Related Author

HE Ren-qiang

LI Pei-fu

ZHANG Ning

GONG Chang-qi

LIU Quan

HE Yiqing

ZHANG Ying

WANG Xi

Related Institution

Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases， Hunan University of Chinese Medicine

Hunan University of Chinese Medicine

MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials

Anhui Province Key Laboratory of Chinese Medicinal Formula

School of Pharmacy，Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰